Cargando…

Development and validation of a decision model for the evaluation of novel lung cancer treatments in the Netherlands

Recent discoveries in molecular diagnostics and drug treatments have improved the treatment of patients with advanced (inoperable) non-squamous non-small cell lung cancer (NSCLC) from solely platinum-based chemotherapy to more personalized treatment, including targeted therapies and immunotherapies....

Descripción completa

Detalles Bibliográficos
Autores principales:	Mfumbilwa, Zakile A., Wilschut, Janneke A., Simons, Martijn J. H. G., Ramaekers, Bram, Joore, Manuela, Retèl, Valesca, der Welle, Christine M. Cramer-van, Schramel, Franz M. N. H., van de Garde, Ewoudt M. W., Coupé, Veerle M. H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911639/ https://www.ncbi.nlm.nih.gov/pubmed/36759641 http://dx.doi.org/10.1038/s41598-023-29286-5

Ejemplares similares

Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer
por: Simons, Martijn J. H. G., et al.
Publicado: (2021)

Trends in Drug Costs and Overall Survival in Patients with Metastatic Non-small Cell Lung Cancer in The Netherlands Diagnosed from 2008 Through 2014
por: Cramer-van der Welle, Christine M., et al.
Publicado: (2020)

Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands
por: Cramer-van der Welle, Christine M., et al.
Publicado: (2021)

Real‐world treatment patterns and outcomes of patients with extensive disease small cell lung cancer
por: Cramer‐van der Welle, Christine M., et al.
Publicado: (2020)

Systematic evaluation of the efficacy–effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer
por: Cramer-van der Welle, Christine M., et al.
Publicado: (2018)

Cost-Effectiveness of Parallel Versus Sequential Testing of Genetic Aberrations for Stage IV Non–Small-Cell Lung Cancer in the Netherlands
por: Wolff, Henri B., et al.
Publicado: (2022)

Whole genome sequencing in oncology: using scenario drafting to explore future developments
por: van de Ven, Michiel, et al.
Publicado: (2021)

Needs with Regard to Decision Support Systems for Treating Patients with Incurable Non-small Cell Lung Cancer
por: Révész, Dóra, et al.
Publicado: (2019)

Next-generation sequencing in NSCLC and melanoma patients: a cost and budget impact analysis
por: van Amerongen, Rosa A, et al.
Publicado: (2016)

Scenario drafting to anticipate future developments in technology assessment
por: Retèl, Valesca P, et al.
Publicado: (2012)

Cost-effectiveness of screening smokers and ex-smokers for lung cancer in the Netherlands in different age groups
por: Al Khayat, Mohamed N. M. T., et al.
Publicado: (2022)

The association between gut microbiome affecting concomitant medication and the effectiveness of immunotherapy in patients with stage IV NSCLC
por: Verschueren, M. V., et al.
Publicado: (2021)

The dynamics in applied COVID-19 pharmacotherapy and the influence of national guidance in The Netherlands: a quantitative and qualitative study
por: Uitvlugt, Elien B, et al.
Publicado: (2022)

Treatment patterns and clinical outcomes of chemotherapy treatment in patients with muscle-invasive or metastatic bladder cancer in the Netherlands
por: Reesink, Daan J., et al.
Publicado: (2020)

‘Care for Outcomes’: systematic development of a set of outcome indicators to improve patient-relevant outcomes for patients with lung cancer
por: Cramer-van der Welle, Christine M, et al.
Publicado: (2021)

Cost-Effectiveness of Surveillance Scanning Strategies after Curative Treatment of Non–Small-Cell Lung Cancer
por: Wolff, Henri B., et al.
Publicado: (2020)

Development and Validation of the TRansparent Uncertainty ASsessmenT (TRUST) Tool for Assessing Uncertainties in Health Economic Decision Models
por: Grimm, Sabine E., et al.
Publicado: (2019)

State of the ART? Two New Tools for Risk Communication in Health Technology Assessments
por: Grimm, Sabine E., et al.
Publicado: (2021)

Building a trusted framework for uncertainty assessment in rare diseases: suggestions for improvement (Response to “TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases”)
por: Grimm, Sabine E., et al.
Publicado: (2021)

Correction to: Building a trusted framework for uncertainty assessment in rare diseases: suggestions for improvement (Response to “TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases”)
por: Grimm, Sabine E., et al.
Publicado: (2021)

A Review on Cost-Effectiveness and Cost-Utility of Psychosocial Care in Cancer Patients
por: Jansen, Femke, et al.
Publicado: (2016)

Cost and cost-effectiveness of adjuvant trastuzumab in the real world setting: A study of the Southeast Netherlands Breast Cancer Consortium
por: Seferina, Shanly C., et al.
Publicado: (2017)

Direct Medical Costs of Advanced Breast Cancer Treatment: A Real-World Study in the Southeast of The Netherlands
por: Schneider, Paul Peter, et al.
Publicado: (2021)

Consecutive antibiotic use in the outpatient setting: an extensive, longitudinal descriptive analysis of antibiotic dispensing data in the Netherlands
por: de Jong, Loek A. W., et al.
Publicado: (2019)

Reviewing the quality, health benefit and value for money of chemotherapy and targeted therapy for metastatic breast cancer
por: Pouwels, Xavier Ghislain Léon Victor, et al.
Publicado: (2017)

Comprehensive Review of Methods to Assess Uncertainty in Health Economic Evaluations
por: Otten, Thomas Michael, et al.
Publicado: (2023)

Data-driven development of the nationwide hip fracture registry in the Netherlands
por: Würdemann, Franka S., et al.
Publicado: (2022)

Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from first-line immunotherapy in NSCLC
por: Ismail, R. K., et al.
Publicado: (2023)

Correction: Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from second-line immunotherapy in NSCLC
por: Ismail, R. K., et al.
Publicado: (2023)

Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study
por: Petersohn, Svenja, et al.
Publicado: (2020)

Supporting participation in paid work of cancer survivors and their partners in the Netherlands: protocol of the SusTained Employability in cancer Patients and their partnerS (STEPS) multi-centre randomized controlled trial and cohort study
por: Zegers, Amber D., et al.
Publicado: (2021)

Prediction of Microscopic Metastases in Patients with Metachronous Oligo-Metastases after Curative Treatment of Non-Small Cell Lung Cancer: A Microsimulation Study
por: Wolff, Henri B., et al.
Publicado: (2021)

Use of Value of Information in Healthcare Decision Making: Exploring Multiple Perspectives
por: Bindels, Jill, et al.
Publicado: (2015)

Understanding the Costs of Surgery: A Bottom-Up Cost Analysis of Both a Hybrid Operating Room and Conventional Operating Room
por: Patel, Sejal, et al.
Publicado: (2020)

An Updated Analysis of the Impact of HPV Vaccination Based on Long-term Effectiveness in the Netherlands
por: Luttjeboer, Jos, et al.
Publicado: (2023)

Treating (low-risk) DCIS patients: What can we learn from real-world cancer registry evidence?
por: Byng, Danalyn, et al.
Publicado: (2021)

The effects of pharmacological interventions on quality of life and fatigue in sarcoidosis: a systematic review
por: Vis, Roeland, et al.
Publicado: (2020)

Scenario drafting for early technology assessment of next generation sequencing in clinical oncology
por: Joosten, S.E.P., et al.
Publicado: (2016)

Variability of cost trajectories over the last year of life in patients with advanced breast cancer in the Netherlands
por: Schneider, Paul P., et al.
Publicado: (2020)

GMP-compliant (68)Ga radiolabelling in a conventional small-scale radiopharmacy: a feasible approach for routine clinical use
por: Vis, Roeland, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_tqmpqgcunvuet0r0mdj5odspjc